Indication
Dawnzera is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
Loading your page…
Loading your page…
Angioedemas, Hereditary
Marketing Authorisation Holder: Otsuka Pharmaceutical Netherlands B.V.
EMA Authorisation: 19/01/2026
INN: donidalorsen
AI Drug & Interaction Analysis
Free account required
Ask Osler about Dawnzera: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.